Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 219

1.

Potential role for second‑generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysis.

Ishikawa M, Iriyama N, Tokuhira M, Takaku T, Sato E, Sugimoto KJ, Nakazato T, Fujita H, Kimura Y, Fujioka I, Komatsu N, Asou N, Kizaki M, Hatta Y, Kawaguchi T.

Oncol Rep. 2019 Sep 27. doi: 10.3892/or.2019.7339. [Epub ahead of print]

PMID:
31578586
2.

A case series of adult T-cell leukemia-lymphoma, associated with human T-cell leukemia virus type-1, at a single center in a non-viral-endemic metropolitan area.

Akuzawa Y, Tsukasaki K, Saeki T, Okamura D, Ishikawa M, Maeda T, Kohri M, Takahashi N, Matsuda A, Kawai N, Asou N.

J Clin Exp Hematop. 2019;59(3):108-111. doi: 10.3960/jslrt.19001.

3.

Author Correction: Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm.

Kubota S, Tokunaga K, Umezu T, Yokomizo-Nakano T, Sun Y, Oshima M, Tan KT, Yang H, Kanai A, Iwanaga E, Asou N, Maeda T, Nakagata N, Iwama A, Ohyashiki K, Osato M, Sashida G.

Nat Commun. 2019 Aug 28;10(1):3943. doi: 10.1038/s41467-019-11919-x.

4.

[Acute promyelocytic leukemia: APL].

Asou N.

Rinsho Ketsueki. 2019;60(3):226-227. doi: 10.11406/rinketsu.60.226. Japanese. No abstract available.

PMID:
31068522
5.

Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm.

Kubota S, Tokunaga K, Umezu T, Yokomizo-Nakano T, Sun Y, Oshima M, Tan KT, Yang H, Kanai A, Iwanaga E, Asou N, Maeda T, Nakagata N, Iwama A, Ohyashiki K, Osato M, Sashida G.

Nat Commun. 2019 Apr 10;10(1):1653. doi: 10.1038/s41467-019-09710-z. Erratum in: Nat Commun. 2019 Aug 28;10(1):3943.

6.

Smoking influences the outcomes of patients receiving tyrosine kinase inhibitors for chronic myeloid leukemia in the chronic phase: A retrospective analysis.

Iriyama N, Tokuhira M, Sato E, Sugimoto KJ, Takaku T, Ishikawa M, Nakazato T, Fujita H, Kimura Y, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T.

Hematol Oncol. 2019 Aug;37(3):323-325. doi: 10.1002/hon.2617. Epub 2019 Apr 26. No abstract available.

PMID:
30950076
7.

TUBB1 dysfunction in inherited thrombocytopenia causes genome instability.

Matsumura T, Nakamura-Ishizu A, Takaoka K, Maki H, Muddineni SSNA, Wang CQ, Suzushima H, Kawakita M, Asou N, Matsuoka M, Kurokawa M, Osato M, Suda T.

Br J Haematol. 2019 Jun;185(5):888-902. doi: 10.1111/bjh.15835. Epub 2019 Mar 10.

PMID:
30854628
8.

False-positive blood culture results in patients with hematologic malignancies.

Ebihara Y, Kobayashi K, Watanabe N, Taji Y, Maeda T, Takahashi N, Ishida A, Asou N, Ikebuchi K.

J Infect Chemother. 2019 May;25(5):404-406. doi: 10.1016/j.jiac.2018.12.010. Epub 2019 Jan 23.

PMID:
30685110
9.

Exome analysis of treatment-related AML after APL suggests secondary evolution.

Wang T, Jacoby MA, Duncavage EJ, Miller CA, Heath S, Rahme R, Fenaux P, Ades L, Renneville A, Cassinat B, Takeshita A, Asou N, Miyazaki Y, Kiyoi H, Ravandi F, Westervelt P, Wartman LD, Welch JS.

Br J Haematol. 2019 Jun;185(5):984-987. doi: 10.1111/bjh.15681. Epub 2018 Nov 22. No abstract available.

PMID:
30467844
10.

The impact of tumor location on the biological and oncological differences of colon cancer: Multi-institutional propensity score-matched study.

Kishiki T, Kuchta K, Matsuoka H, Kojima K, Asou N, Beniya A, Yamauchi S, Sugihara K, Masaki T.

Am J Surg. 2019 Jan;217(1):46-52. doi: 10.1016/j.amjsurg.2018.07.005. Epub 2018 Jul 10.

PMID:
30384969
11.

The progression of severe aplastic anemia to hypoplastic leukemia in a long-term observation after the administration of pegylated rHuMGDF.

Ishikawa M, Matsuda A, Okamura D, Maeda T, Kawai N, Asou N, Bessho M.

Hematol Rep. 2018 Sep 5;10(3):7679. doi: 10.4081/hr.2018.7679. eCollection 2018 Sep 5.

12.

Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.

Kawashima N, Akashi A, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, Miyawaki S, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kitamura K, Sakaida E, Takeshita A, Suzushima H, Naoe T, Matsumura I, Miyazaki Y, Ogawa S, Kiyoi H; Japan Adult Leukemia Study Group (JALSG).

Ann Hematol. 2019 Jan;98(1):83-91. doi: 10.1007/s00277-018-3492-5. Epub 2018 Sep 24.

PMID:
30251205
13.

Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis.

Iriyama N, Sugimoto KJ, Sato E, Takaku T, Tokuhira M, Nakazato T, Ishikawa M, Fujita H, Fujioka I, Kimura Y, Asou N, Kizaki M, Komatsu N, Hatta Y, Kawaguchi T.

Med Oncol. 2018 Sep 7;35(11):142. doi: 10.1007/s12032-018-1203-7.

PMID:
30194496
14.

Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study.

Takeshita A, Asou N, Atsuta Y, Sakura T, Ueda Y, Sawa M, Dobashi N, Taniguchi Y, Suzuki R, Nakagawa M, Tamaki S, Hagihara M, Fujimaki K, Furumaki H, Obata Y, Fujita H, Yanada M, Maeda Y, Usui N, Kobayashi Y, Kiyoi H, Ohtake S, Matsumura I, Naoe T, Miyazaki Y; and the Japanese Adult Leukemia Study Group.

Leukemia. 2019 Feb;33(2):358-370. doi: 10.1038/s41375-018-0233-7. Epub 2018 Aug 9.

PMID:
30093681
15.

Recent trends (2016-2017) in the treatment of inflammatory bowel disease.

Masaki T, Kishiki T, Kojima K, Asou N, Beniya A, Matsuoka H.

Ann Gastroenterol Surg. 2018 Jun 2;2(4):282-288. doi: 10.1002/ags3.12177. eCollection 2018 Jul. Review.

16.

[Acute promyelocytic leukemia: state-of-the-art management].

Asou N.

Rinsho Ketsueki. 2018;59(6):725-734. doi: 10.11406/rinketsu.59.725. Review. Japanese.

PMID:
29973452
17.

Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database.

Fujioka I, Takaku T, Iriyama N, Tokuhira M, Kimura Y, Sato E, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T.

Ann Hematol. 2018 Nov;97(11):2081-2088. doi: 10.1007/s00277-018-3412-8. Epub 2018 Jun 26.

PMID:
29946911
18.

Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors.

Nakazato T, Iriyama N, Tokuhira M, Ishikawa M, Sato E, Takaku T, Sugimoto KJ, Fujita H, Fujioka I, Kimura Y, Aisa Y, Iwanaga E, Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T.

Med Oncol. 2018 May 30;35(7):99. doi: 10.1007/s12032-018-1159-7.

PMID:
29846829
19.

Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase.

Tokuhira M, Kimura Y, Sugimoto K, Nakazato T, Ishikawa M, Fujioka I, Takaku T, Iriyama N, Sato E, Fujita H, Hatta Y, Komatsu N, Asou N, Kizaki M, Kawaguchi T.

Med Oncol. 2018 Feb 13;35(3):38. doi: 10.1007/s12032-018-1093-8.

PMID:
29442179
20.

Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study.

Harada Y, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, Miyawaki S, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Onizuka M, Takeshita A, Ishida F, Suzushima H, Ishizawa K, Naoe T, Matsumura I, Miyazaki Y, Ogawa S, Kiyoi H; Japan Adult Leukemia Study Group JALSG.

Leuk Res. 2018 Mar;66:20-27. doi: 10.1016/j.leukres.2018.01.008. Epub 2018 Jan 17.

PMID:
29360622
21.

Distinct gene alterations with a high percentage of myeloperoxidase-positive leukemic blasts in de novo acute myeloid leukemia.

Kamijo R, Itonaga H, Kihara R, Nagata Y, Hata T, Asou N, Ohtake S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, Naoe T, Kiyoi H, Miyazaki Y.

Leuk Res. 2018 Feb;65:34-41. doi: 10.1016/j.leukres.2017.12.006. Epub 2018 Jan 2.

PMID:
29306105
22.

Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia.

Kuwatsuka Y, Tomizawa D, Kihara R, Nagata Y, Shiba N, Iijima-Yamashita Y, Shimada A, Deguchi T, Miyachi H, Tawa A, Taga T, Kinoshita A, Nakayama H, Kiyokawa N, Saito AM, Koh K, Goto H, Kosaka Y, Asou N, Ohtake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Ogawa S, Naoe T, Hayashi Y, Horibe K, Manabe A, Mizutani S, Adachi S, Kiyoi H.

Int J Hematol. 2018 Feb;107(2):201-210. doi: 10.1007/s12185-017-2340-z. Epub 2017 Oct 12.

PMID:
29027108
23.

Myeloid neoplasms in the World Health Organization 2016 classification.

Asou N.

Rinsho Ketsueki. 2017;58(10):2178-2187. doi: 10.11406/rinketsu.58.2178. Japanese.

PMID:
28978863
24.

High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG.

Sakura T, Hayakawa F, Sugiura I, Murayama T, Imai K, Usui N, Fujisawa S, Yamauchi T, Yujiri T, Kakihana K, Ito Y, Kanamori H, Ueda Y, Miyata Y, Kurokawa M, Asou N, Ohnishi K, Ohtake S, Kobayashi Y, Matsuo K, Kiyoi H, Miyazaki Y, Naoe T.

Leukemia. 2018 Mar;32(3):626-632. doi: 10.1038/leu.2017.283. Epub 2017 Sep 15.

PMID:
28914260
25.

JSH guideline for tumors of hematopoietic and lymphoid tissues: leukemia: 2. Acute promyelocytic leukemia (APL).

Asou N, Fujita H, Shinagawa K.

Int J Hematol. 2017 Oct;106(4):459-470. doi: 10.1007/s12185-017-2318-x. Epub 2017 Aug 30. No abstract available.

PMID:
28856623
26.

Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score.

Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T.

Leuk Lymphoma. 2018 May;59(5):1105-1112. doi: 10.1080/10428194.2017.1365858. Epub 2017 Aug 25.

PMID:
28838287
27.

[II.Acute Myeloid Leukemia].

Asou N.

Gan To Kagaku Ryoho. 2017 May;44(5):386-391. Japanese. No abstract available.

PMID:
28536333
28.

Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia.

Togasaki E, Takeda J, Yoshida K, Shiozawa Y, Takeuchi M, Oshima M, Saraya A, Iwama A, Yokote K, Sakaida E, Hirase C, Takeshita A, Imai K, Okumura H, Morishita Y, Usui N, Takahashi N, Fujisawa S, Shiraishi Y, Chiba K, Tanaka H, Kiyoi H, Ohnishi K, Ohtake S, Asou N, Kobayashi Y, Miyazaki Y, Miyano S, Ogawa S, Matsumura I, Nakaseko C, Naoe T.

Blood Cancer J. 2017 Apr 28;7(4):e559. doi: 10.1038/bcj.2017.36.

29.

Diagnostic performance of procalcitonin, presepsin, and C-reactive protein in patients with hematological malignancies.

Ebihara Y, Kobayashi K, Ishida A, Maeda T, Takahashi N, Taji Y, Asou N, Ikebuchi K.

J Clin Lab Anal. 2017 Nov;31(6). doi: 10.1002/jcla.22147. Epub 2017 Jan 30.

PMID:
28133789
30.

Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group.

Iriyama N, Tokuhira M, Takaku T, Sato E, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Fujioka I, Hatta Y, Kizaki M, Komatsu N, Asou N, Kawaguchi T.

Leuk Res. 2017 Mar;54:55-58. doi: 10.1016/j.leukres.2017.01.003. Epub 2017 Jan 5.

PMID:
28109974
31.

Prognostic stratification in the treatment of AML.

Asou N.

Rinsho Ketsueki. 2016;57(10):1918-1927. Japanese.

PMID:
27725589
32.

Lineage switch with t(6;11)(q27;q23) from T-cell lymphoblastic lymphoma to acute monoblastic leukemia at relapse.

Higuchi Y, Tokunaga K, Watanabe Y, Kawakita T, Harada N, Yamaguchi S, Nosaka K, Mitsuya H, Asou N.

Cancer Genet. 2016 Jun;209(6):267-71. doi: 10.1016/j.cancergen.2016.05.070. Epub 2016 May 18.

PMID:
27268298
33.

Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study.

Ogura M, Imaizumi Y, Uike N, Asou N, Utsunomiya A, Uchida T, Aoki T, Tsukasaki K, Taguchi J, Choi I, Maruyama D, Nosaka K, Chen N, Midorikawa S, Ohtsu T, Tobinai K.

Lancet Haematol. 2016 Mar;3(3):e107-18. doi: 10.1016/S2352-3026(15)00284-7. Epub 2016 Feb 12.

PMID:
26947199
34.

Unrelated bone marrow transplantation or immediate umbilical cord blood transplantation for patients with acute myeloid leukemia in first complete remission.

Yanada M, Kanda J, Ohtake S, Fukuda T, Sakamaki H, Miyamura K, Miyawaki S, Uchida N, Maeda T, Nagamura-Inoue T, Asou N, Morishima Y, Atsuta Y, Miyazaki Y, Kimura F, Kobayashi Y, Takami A, Naoe T, Kanda Y.

Eur J Haematol. 2016 Sep;97(3):278-87. doi: 10.1111/ejh.12723. Epub 2016 Jan 20.

PMID:
26680003
35.

Proposal of criteria for dyserythropoiesis in the diagnosis of myelodysplastic syndromes.

Kawai N, Matsuda A, Jinnai I, Ichimura T, Kayano H, Okamura D, Ishikawa M, Maeda T, Hata T, Miyazaki Y, Asou N, Bessho M, Tomonaga M.

Int J Hematol. 2016 Feb;103(2):227-33. doi: 10.1007/s12185-015-1916-8. Epub 2015 Nov 25.

PMID:
26608365
36.

Disease evolution and outcomes in familial AML with germline CEBPA mutations.

Tawana K, Wang J, Renneville A, Bödör C, Hills R, Loveday C, Savic A, Van Delft FW, Treleaven J, Georgiades P, Uglow E, Asou N, Uike N, Debeljak M, Jazbec J, Ancliff P, Gale R, Thomas X, Mialou V, Döhner K, Bullinger L, Mueller B, Pabst T, Stelljes M, Schlegelberger B, Wozniak E, Iqbal S, Okosun J, Araf S, Frank AK, Lauridsen FB, Porse B, Nerlov C, Owen C, Dokal I, Gribben J, Smith M, Preudhomme C, Chelala C, Cavenagh J, Fitzgibbon J.

Blood. 2015 Sep 3;126(10):1214-23. doi: 10.1182/blood-2015-05-647172. Epub 2015 Jul 10.

PMID:
26162409
37.

Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trial.

Shinagawa K, Yanada M, Sakura T, Ueda Y, Sawa M, Miyatake J, Dobashi N, Kojima M, Hatta Y, Emi N, Tamaki S, Gomyo H, Yamazaki E, Fujimaki K, Asou N, Matsuo K, Ohtake S, Miyazaki Y, Ohnishi K, Kobayashi Y, Naoe T.

J Clin Oncol. 2014 Nov 20;32(33):3729-35. doi: 10.1200/JCO.2013.53.3570. Epub 2014 Sep 22. Erratum in: J Clin Oncol. 2015 Jan 10;33(2):228.

PMID:
25245439
38.

Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine.

Okamura D, Matsuda A, Ishikawa M, Maeda T, Tanae K, Kohri M, Takahashi N, Kawai N, Asou N, Bessho M.

Leuk Res Rep. 2014 Apr 16;3(1):24-7. doi: 10.1016/j.lrr.2014.03.002. eCollection 2014.

39.

Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients.

Kihara R, Nagata Y, Kiyoi H, Kato T, Yamamoto E, Suzuki K, Chen F, Asou N, Ohtake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Kiguchi T, Imai K, Uike N, Kimura F, Kitamura K, Nakaseko C, Onizuka M, Takeshita A, Ishida F, Suzushima H, Kato Y, Miwa H, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, Naoe T.

Leukemia. 2014 Aug;28(8):1586-95. doi: 10.1038/leu.2014.55. Epub 2014 Feb 3.

PMID:
24487413
40.

IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.

Yamaguchi S, Iwanaga E, Tokunaga K, Nanri T, Shimomura T, Suzushima H, Mitsuya H, Asou N.

Eur J Haematol. 2014 Jun;92(6):471-7. doi: 10.1111/ejh.12271. Epub 2014 Mar 3.

PMID:
24443894
41.

Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome.

Iriyama N, Asou N, Miyazaki Y, Yamaguchi S, Sato S, Sakura T, Maeda T, Handa H, Takahashi M, Ohtake S, Hatta Y, Sakamaki H, Honda S, Taki T, Taniwaki M, Miyawaki S, Ohnishi K, Kobayashi Y, Naoe T.

Ann Hematol. 2014 Jun;93(6):957-63. doi: 10.1007/s00277-014-2013-4. Epub 2014 Jan 19.

PMID:
24441947
42.

Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts.

Ono T, Takeshita A, Kishimoto Y, Kiyoi H, Okada M, Yamauchi T, Emi N, Horikawa K, Matsuda M, Shinagawa K, Monma F, Ohtake S, Nakaseko C, Takahashi M, Kimura Y, Iwanaga M, Asou N, Naoe T; Japan Adult Leukemia Study Group.

Cancer Sci. 2014 Jan;105(1):97-104. doi: 10.1111/cas.12319. Epub 2014 Jan 9.

43.

Akt-induced phosphorylation of N-CoR at serine 1450 contributes to its misfolded conformational dependent loss (MCDL) in acute myeloid leukemia of the M5 subtype.

Nin DS, Ali AB, Okumura K, Asou N, Chen CS, Chng WJ, Khan M.

PLoS One. 2013 Aug 5;8(8):e70891. doi: 10.1371/journal.pone.0070891. Print 2013.

44.

Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97.

Fujita H, Asou N, Iwanaga M, Hyo R, Nomura S, Kiyoi H, Okada M, Inaguma Y, Matsuda M, Yamauchi T, Ohtake S, Izumi T, Nakaseko C, Ishigatsubo Y, Shinagawa K, Takeshita A, Miyazaki Y, Ohnishi K, Miyawaki S, Naoe T; Japan Adult Leukemia Study Group.

Cancer Sci. 2013 Oct;104(10):1339-45. doi: 10.1111/cas.12230. Epub 2013 Aug 5.

45.

The demarcation between younger and older acute myeloid leukemia patients: a pooled analysis of 3 prospective studies.

Yanada M, Ohtake S, Miyawaki S, Sakamaki H, Sakura T, Maeda T, Miyamura K, Asou N, Oh I, Miyatake J, Kanbayashi H, Takeuchi J, Takahashi M, Dobashi N, Kiyoi H, Miyazaki Y, Emi N, Kobayashi Y, Ohno R, Naoe T; Japan Adult Leukemia Study Group.

Cancer. 2013 Sep 15;119(18):3326-33. doi: 10.1002/cncr.28212. Epub 2013 Jun 24.

46.

High frequency of IKZF1 genetic alterations in adult patients with B-cell acute lymphoblastic leukemia.

Tokunaga K, Yamaguchi S, Iwanaga E, Nanri T, Shimomura T, Suzushima H, Mitsuya H, Asou N.

Eur J Haematol. 2013 Sep;91(3):201-8. doi: 10.1111/ejh.12155. Epub 2013 Jul 7.

PMID:
23751147
47.

[Treatment of previously untreated acute promyelocytic leukemia].

Asou N.

Nihon Rinsho. 2012 Apr;70 Suppl 2:415-9. Japanese. No abstract available.

PMID:
23133992
48.

[Molecular pathophysiology and diagnosis of acute myeloid leukemia].

Asou N.

Rinsho Ketsueki. 2012 Oct;53(10):1549-59. Review. Japanese. No abstract available.

PMID:
23037727
49.

Long-term outcome and prognostic factors of elderly patients with acute promyelocytic leukemia.

Ono T, Takeshita A, Kishimoto Y, Kiyoi H, Okada M, Yamauchi T, Tsuzuki M, Horikawa K, Matsuda M, Shinagawa K, Monma F, Ohtake S, Nakaseko C, Takahashi M, Kimura Y, Iwanaga M, Asou N, Naoe T; Japan Adult Leukemia Study Group.

Cancer Sci. 2012 Nov;103(11):1974-8. doi: 10.1111/j.1349-7006.2012.02390.x. Epub 2012 Sep 18.

50.

Eμ/miR-125b transgenic mice develop lethal B-cell malignancies.

Enomoto Y, Kitaura J, Hatakeyama K, Watanuki J, Akasaka T, Kato N, Shimanuki M, Nishimura K, Takahashi M, Taniwaki M, Haferlach C, Siebert R, Dyer MJ, Asou N, Aburatani H, Nakakuma H, Kitamura T, Sonoki T.

Leukemia. 2011 Dec;25(12):1849-56. doi: 10.1038/leu.2011.166. Epub 2011 Jul 8.

PMID:
21738213

Supplemental Content

Support Center